Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this phase 1 study is to investigate the absolute bio-availability of
a single oral dose of selexipag, i.e., to assess the amount of selexipag which reaches the
blood when administered as an oral tablet (ACT-293987) compared to an intravenous
administration in healthy subjects.